Bayer's Off-Label Yaz Marketing Violated FCA: Watchdog
A pharmaceutical company watchdog accused Bayer Schering Pharma AG of marketing its Yasmin and Yaz contraceptives for unapproved purposes and causing doctors to seek Medicaid reimbursements for off-label prescriptions of those...To view the full article, register now.
Already a subscriber? Click here to view full article